
Choosing an HS Biologic: Comorbidities, Access, and Adherence Barriers
With three approved biologics and no head-to-head data, comorbidities and timely access guide the choice. Practical barriers and unmet expectations quietly undermine adherence.
Episodes in this series

This episode, "Choosing an HS Biologic: Comorbidities, Access, and Adherence Barriers," features Dr. Hsiao working through how she selects a first biologic.
Dr. Hsiao notes that three biologics are currently approved for HS. These are adalimumab, a TNF alpha inhibitor, secukinumab, an IL-17A inhibitor, and bimekizumab, an IL-17A and F inhibitor. She starts her selection with the patient's comorbidities. A patient with lupus or severe congestive heart failure warrants an IL-17 inhibitor rather than a TNF antagonist. A patient with inflammatory bowel disease calls for the opposite choice, a TNF alpha antagonist.
No head-to-head studies compare the three agents, and responses are heterogeneous. Some patients respond well to a TNF alpha inhibitor, lose efficacy, and then respond less robustly to an IL-17 inhibitor. Others do poorly on TNF alpha therapy and have an amazing response to an IL-17 inhibitor. Dr. Hsiao says there is no silver bullet in HS.
Her most important point is to start the biologic once a patient is open to it. Spending six months on access problems means losing time while the disease may be progressing. Access also shapes the final choice, often through formularies and payers.
She then describes practical challenges in starting biologics. Some patients are needle averse or unready for a long-term injectable, though she feels this has become less of an issue in the era of GLP-1 agonists. HS is also associated with lower socioeconomic status, and some of her patients lack consistent refrigeration for storing biologics.
Dr. Hsiao says one of the biggest threats to adherence over time is perceived lack of adequate efficacy. That may reflect a true lack of efficacy, expectations that were never set, or loss of efficacy over time.
The next episode in this series, "Inadequate Disease Control in HS: Treatment Escalation and Dual Targeted Therapy," examines what she does when patients still lack adequate control.
Related to this article






